Merck (NYSE:MRK), one of the most recognizable names in the pharmaceutical industry, is devoted to the development of new drugs that can treat a wide range of afflictions, from diabetes to cancer.
So why is it collaborating with technology giant Samsung?
Well, it's not quite what you think. Today, Merck announced a partnership with Samsung Bioepis, a joint venture between Samsung's biologics unit and biotech company Biogen Idec. In this video, health-care analyst Max Macaluso discusses the detai mls of this deal and how it fits into Merck's total business.